KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 89 filers reported holding KEROS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,447,522 | -20.7% | 1,676,522 | 0.0% | 0.10% | -18.6% |
| Q2 2023 | $67,362,653 | -6.0% | 1,676,522 | -0.1% | 0.12% | -25.3% |
| Q1 2023 | $71,651,368 | +7.2% | 1,678,018 | +20.5% | 0.16% | -38.8% |
| Q4 2022 | $66,863,144 | +47.0% | 1,392,402 | +15.2% | 0.26% | +75.5% |
| Q3 2022 | $45,475,000 | +39.9% | 1,208,822 | +2.8% | 0.15% | +69.0% |
| Q2 2022 | $32,505,000 | -34.1% | 1,176,433 | +29.8% | 0.09% | -12.1% |
| Q1 2022 | $49,291,000 | -9.1% | 906,433 | -2.2% | 0.10% | -1.0% |
| Q4 2021 | $54,205,000 | +95.3% | 926,433 | +32.1% | 0.10% | +112.8% |
| Q3 2021 | $27,748,000 | -7.1% | 701,433 | -0.3% | 0.05% | +6.8% |
| Q2 2021 | $29,875,000 | -7.3% | 703,439 | +34.4% | 0.04% | -8.3% |
| Q1 2021 | $32,218,000 | -12.5% | 523,439 | +0.3% | 0.05% | -20.0% |
| Q4 2020 | $36,830,000 | +3083.2% | 522,121 | +1640.4% | 0.06% | +2900.0% |
| Q3 2020 | $1,157,000 | +2.8% | 30,000 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $1,125,000 | – | 30,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |